maltulose

A glycosylfructose consisting of an alpha-D-glucopyranosyl residue joined to beta-D-fructofuranose via a (1->4)-linkage.


name: Vulvar Neoplasm of Skin Appendage Origin

category: biolink:Disease biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

description: A benign or malignant vulvar neoplasm with differentiating characteristics towards sweat or sebaceous glands or hair follicles.  Representative examples include trichoepithelioma, syringoma, and eccrine adenocarcinoma.


Malignant Vulvar Sweat Gland Neoplasm

description: A malignant neoplasm that arises from sweat glands in the vulva. Representative examples include eccrine adenocarcinoma, apocrine adenocarcinoma, and Paget disease.


Vulvar Hidradenoma Papilliferum

description: A benign glandular neoplasm that arises from the vulva. It presents as a mass or cystic lesion in or adjacent to the interlabial sulcus. It is characterized by the presence of complex branching papillae with fibrovascular stalks, lined by uniform columnar epithelial secretory cells and myoepithelial cells.


name: Vulvar Adenocarcinoma of Sweat Gland Origin

description: A rare adenocarcinoma arising from vulvar skin sweat glands.


name: Cirrhosis of the Liver Secondary to Hepatitis C

description: Cirrhosis of the liver that develops as a sequelae of a hepatitis c infection.


name: Definite Residual Metabolic Tumor Activity

category: biolink:PhenotypicFeature biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

description: A finding of strong focal metabolic activity at the primary or nodal sites that is greater than liver uptake.


A member of the class of triazoles that is 1H-1,2,4-triazole substituted by (1E)-3-amino-2-{4-[(methylsulfonyl)amino]phenyl}-3-oxoprop-1-en-1-yl and 3,5-bis(trifluoromethyl)phenyl groups at positions 1 and 3, respectively. It is an exportin 1 inhibitor.


lactogangliotetraosylceramide

A glycotetraosylceramide Having N-acetyl-beta-D-galactosaminyl-(1->3)-[N-acetyl-beta-D-galactosaminyl-(1->4)-beta-D-galactosyl-(1->4)]-beta-D-glucosyl as the glycotetraosyl component and which is acylated on the amino group by a tetracosanoyl group. A leukaemia-associated antigen with an unusual branching structure.


4alpha-hydroxymethyl steroid

Any steroid which is substituted by a hydroxymethyl group at the 4alpha position.


Any steroid which is substituted by a hydroxymethyl group at position 4.


Any 3beta-hydroxy steroid which is substituted at the 4alpha and 4beta positions by hydroxymethyl and methyl groups, respectively.


4beta-hydroxymethyl steroid

Any steroid which is substituted by a hydroxymethyl group at the 4beta position.


A 4alpha-hydroxymethyl steroid that is 5-alpha-cholest-7-en-3beta-ol in which the alpha-hydrogen at position 4 has been replaced by a hydroxymethyl group.


Any 3beta-hydroxy steroid which is substituted at the 4alpha and 4beta positions by methyl and hydroxymethyl groups, respectively.


A 3beta-hydroxy-4beta-hydroxymethyl-4alpha-methylsteroid that is 14-demethyllanosterol in which the methyl group at the 4beta position has been oxidised to the corresponding hydroxymethyl group.


(2S,4S)-hypoglycin B

An L-glutamyl amino acid that is (2S,4S)-hypoglycin A in which the amino group has been acylated by the gamma-carboxy group of L-glutamic acid.


(2S,4R)-hypoglycin B

A 5-L-glutamyl amino acid resulting from the formal condensation of the amino group of (2S,4R)-hypoglycin A with the gamma-carboxy group of L-glutamic acid.


dehydrocitreoisocoumarin

A member of the class of isocoumarins that is 1H-isochromen-1-one substituted by a 2,4-dioxopentyl group at position 3 and by hydroxy groups at positions 6 and 8.


Stage IIA2 Cervical Cancer FIGO 2018

description: Cervical carcinoma limited to the upper two-thirds of the vagina without parametrial involvement, equal or more than 4 cm in greatest dimension. (FIGO 2018)


(+)-N-methylconiine

A piperidine that is (+)-coniine bering an N-methyl substituent.


name: Grade 3 Lymphatic Infection with Unknown Absolute Neutrophil Count, CTCAE


Any member of the class of 1,3,5-triazines substituted by at least one methoxy group.


acetoguanamine

A diamino-1,3,5-triazine that is 1,3,5-triazine-2,4-diamine carrying an additional methyl substituent at position 6.


triflusulfuron

An N-sulfonylurea that is urea in which a hydrogen attached to one of the nitrogens has been replaced by a (2-carboxy-6-methylphenyl)sulfonyl group, while a hydrogen attached to the other nitrogen has been replaced by a 4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl group. An acetolactate synthase inhibitor, it is used (generally as the corresponding methyl ester proherbicide) to control annual and perennial broad-leaved weeds in sugar beet and other crops.


metribuzin-diketo

A member of the class of  1,2,4-triazines that is 1,2,4-triazine-3,5(2H,4H)-dione substituted by an amino group at position 4 and a tert-butyl group at position 6. It is a metabolite of metribuzin.


name: 3-[[4,6-bis(4-morpholinyl)-1,3,5-triazin-2-yl]amino]-3-(2-chlorophenyl)propanoic acid ethyl ester


triazine

Any of three isomers generated by replacing three of the carbon atoms of benzene with nitrogen atoms.


naphthyridine

Any one of eight organic heterobicyclic compounds that have a naphthalene skeleton in which two of the carbons are replaced by nitrogens. A 'closed' class.


(R)-secbumeton

The (R)-enantiomer of N-(butan-2-yl)-N'-ethyl-6-methoxy-1,3,5-triazine-2,4-diamine.


enasidenib

A 1,3,5-triazine which is substituted by (2-hydroxy-2-methylpropyl)nitrilo, 6-(trifluoromethyl)pyridin-2-yl and [2-(trifluoromethyl)pyridin-4-yl]nitrilo groups at positions 2,4 and 6, respectively. It is an isocitrate dehydrogenase-2 (IDH2) inhibitor which has been approved for the treatment of adults with relapsed or refractory acute myeloid leukaemia (AML).


terbutylazine-desethyl

A diamino-1,3,5-triazine that is 1,3,5-triazine-2,4-diamine substituted by a tert-butyl group at the amino nitrogen and a chloro group at position 6. It is metabolite of the herbicide terbutylazine.


(R)-triaziflam

An N-[1-(3,5-dimethylphenoxy)propan-2-yl]-6-(2-fluoropropan-2-yl)-1,3,5-triazine-2,4-diamine that is the (R)-enantiomer of triaziflam.


procion red MX-5B

A 2,4-dichloro-1,3,5-triazine with a multi-substituted napthalen-1-ylamino substituent at the 6-position.


An N-(2,6-dimethylindan-1-yl)-6-(1-fluoroethyl)-1,3,5-triazine-2,4-diamine in which the indane moiety has 1R,2S configuration and the fluoroethyl substituent has S configuration. A cellulose biosynthesis inhibitor, it is the minor component of the herbicide indaziflam.


A monoamino-1,3,5-triazine that is 1,3,5-triazin-2-amine substituted by a methoxy group at position 4 and a methyl group at position 6. It is a metabolite of the herbicide thifensulfuron-methyl.


irgarol 1051

A diamino-1,3,5-triazine that is  1,3,5-triazine-2,4-diamine carrying a N-tert-butyl, N'-cyclopropyl and a methylsulfanyl group at position 6.


A tetrazole tautomer where the proton is located on the 2 position.


PROMETRYN

A diamino-1,3,5-triazine that is N,N'-di(propan-2-yl)-1,3,5-triazine-2,4-diamine substituted by a methylsulfanediyl group at position 6.


CINNOLINE

An azaarene that is the 1,2-diaza analogue of naphthalene. The parent of the class of cinnolines.


(S)-triaziflam

An N-[1-(3,5-dimethylphenoxy)propan-2-yl]-6-(2-fluoropropan-2-yl)-1,3,5-triazine-2,4-diamine that is the (S)-enantiomer of triaziflam.


ISOQUINOLINE

An ortho-fused heteroarene that is a benzopyridine in which the N atom not directly attached to the benzene ring.


1,3,5-triazinylamino nitrile

Any diamino-1,3,5-triazine in which the amino group is substituted by at least one cyano group.


N-cyclopropylammelide

A dihydroxy-1,3,5-triazine consisting of ammelide bearing an N-cyclohexyl substituent.


A monohydroxy-1,3,5-triazine that is  atrazine in which the chloro group has been replaced by a hydroxy group.


ETHAMETSULFURON METHYL

A methyl ester resulting from the formal condensation of the carboxy group of ethametsulfuron with methanol. A herbicide used for the control of broad-leaved weeds in oil seed rape and fodder rape.


Any compound with a 1,2,4-triazine skeleton, in which nitrogen atoms replace carbon at positions 1, 2 and 4 of the core benzene ring structure.


6-AZA-URIDINE MONOPHOSPHATE

A N-glycosyl-1,2,4-triazine that is the 6-aza analogue of uridine 5'-monophosphate.


An N-(2,6-dimethylindan-1-yl)-6-(1-fluoroethyl)-1,3,5-triazine-2,4-diamine in which the indane moiety has 1R,2S configuration and the fluoroethyl substituent has R configuration. A cellulose biosynthesis inhibitor, it is the major active component of the herbicide indaziflam.


PHTHALAZINE

An azaarene that is the 2,3-diaza analogue of naphthalene. The parent of the class of phthalazines.


FAZARABINE

An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-arabinofuranosyl residue via an N-glycosidic linkage. A synthetic analogue of cytosine arabinoside and 5-azacytidine that incorporates structural features of both compounds, it shows good activity against a variety of transplanted tumors.


A dihydroxy-1,3,5-triazine that is 1,3,5-triazine-2,4-diol substituted by a chloro group at position 6.


(S)-secbumeton

The (S)-enantiomer of N-(butan-2-yl)-N'-ethyl-6-methoxy-1,3,5-triazine-2,4-diamine.


ethametsulfuron

An N-sulfonylurea that is urea in which one of the nitrogens has been substituted by a 4-ethoxy-6-(methylamino)-1,3,5-triazin-2-yl group, while the other has been substituted by a (2-carboxyphenyl)sulfonyl group.


terbumeton

A diamino-1,3,5-triazine that is N-tert-butyl-N'-ethyl-1,3,5-triazine-2,4-diamine substituted by a methoxy group at position 6. It is an agrochemical used as a herbicide.


Any compound with a 1,3,5-triazine skeleton, in which nitrogen atoms replace carbon at positions 1, 3 and 5 of the core benzene ring structure.


procion orange MX-2R

A 2,4-dichloro-1,3,5-triazine with a multi-substituted napthalen-2-yldiazenyl substituent at the 6-position.


6-azathymidine 5'-monophosphate

A N-glycosyl-1,2,4-triazine that is the 6-aza analogue of thymidine 5'-monophosphate.


Any member of the class of 1,3,5-triazines that consists of a 1,3,5-triazine skeleton substituted by two amino groups.


A diamino-1,3,5-triazine that is N-(butan-2-yl)-N'-ethyl-1,3,5-triazine-2,4-diamine substituted by a chloro group at position 6.


tribenuron

An N-sulfonylurea that is N-(2-carboxybenzenesulfonyl)urea bearing additional methyl and 4-methoxy-6-methyl-1,3,5-triazin-2-yl substituents at position N3. A foliar acting, post-emergence herbicide used to control broad-leaved weeds in cereals, normally used as the methyl variant.


A 1,2,4-triazine compound having oxo-substituents at the 3- and 5-positions.


A monoamino-1,3,5-triazine that is cytosine in which the aromatic CH at position 5 is replaced by a nitrogen.


TRIBENURON METHYL

The methyl ester of tribenuron.


A member of the class of indanes that is 2,5-dimethylindane in which the hydrogen at position 3 has been replaced by one of the primary amino groups of 6-(1-fluoroethyl)-1,3,5-triazine-2,4-diamine.


metamitron-desamino

A member of the class of 1,2,4-triazines that is  metamitron in which the amino group has been replaced by a hydrogen atom. It is a metabolite of  metamitron.


A nucleobase analogue that is thymine in which the CH group at position 6 is replaced by nitrogen.


SIMETRYN

A diamino-1,3,5-triazine that is N,N'-diethyl-1,3,5-triazine-2,4-diamine substituted by a methylthio group at position 6.


CHLORSULFURON

An N-sulfonylurea that is N-carbamoyl-2-chlorobenzenesulfonamide in which one of the hydrogens attached to the non-sulfonylated nitrogen has been replaced by a 4-methoxy-6-methyl-1,3,5-triazin-2-yl group. A herbicide used for the control of broadleaf weeds in wheat, barley and oats.


triflusulfuron-methyl

A methyl ester resulting from the formal condensation of the carboxy group of triflusulfuron with methanol. A proherbicide for triflusulfuron.


name: 5-oxo-3-sulfanylidene-2H-1,2,4-triazine-6-carboxylic acid ethyl ester


PROMETON

A  methoxy-1,3,5-triazine that is 6-methoxy-1,3,5-triazine-2,4-diamine in which the one of the hydrogens of each amino group is substituted by an isopropyl group.


THIFENSULFURON-METHYL

A methyl ester resulting from the formal condensation of the carboxy group of thifensulfuron with methanol. It is used  as a post-emergence herbicide for the control of grass and broad-leaved weeds.


A diamino-1,3,5-triazine that is 1,3,5-triazine substituted by a [1-(3,5-dimethylphenoxy)propan-2-yl]nitrilo group, amino group and 2-fluoropropan-2-yl group at positions 2,4 and 6, respectively.


A diamino-1,3,5-triazine that is N-(propan-2-yl)-1,3,5-triazine-2,4-diamine substituted by a hydroxy group at position 2. It is a metabolite of the herbicide atrazine.


An organosulfonic acid comprising stilbene having 4-anilino-6-[bis(2-hydroxyethyl)amino]-1,3,5-triazin-2-yl}amino groups at the 4 and 4'-positions and sulfo groups at the 2- and 2'-positions.


(R)-sebuthylazine

The (R)-enantiomer of N-(butan-2-yl)-6-chloro-N'-ethyl-1,3,5-triazine-2,4-diamine.


simeton

A methoxy-1,3,5-triazine that is  6-methoxy-1,3,5-triazine-2,4-diamine in which one of the hydrogens of each amino group has been replaced by an ethyl group.


iofensulfuron

An N-sulfonylurea that is N-carbamoyl-2-iodobenzenesulfonamide bearing a 4-methoxy-6-methyl-1,3,5-triazin-2-yl substituent at position N3.


cyanuric chloride

A chloro-1,3,5-triazine in which the triazine ring is substituted on each carbon by chlorine. Its main use is in the preparation of the triazine-class pesticides.


tetrazole

An  azaarene that is a five-membered ring composed of 4 nitrogen and 1 carbon atom.


A diamino-1,3,5-triazine that is 1,3,5-triazine-2,4-diamine substituted by a methylsulfanyl group at position 6 and a tert-buty group at the amino nitrogen atom.


cycloguanil

A triazine in which a 1,6-dihydro-1,3,5-triazine ring is substituted at N-1 by a 4-chlorophenyl group, at C-2 and -4 by amino groups and at C-6 by gem-dimethyl groups. A dihydrofolate reductase inhibitor, it is a metabolite of the antimalarial drug proguanil.


A diamino-1,3,5-triazine that is 1,3,5-triazin-2-ol substituted by a tert-butylamino group at position 4 and an ethylamino group at position 6. It is a metabolite of the herbicide terbutylazine,


secbumeton

A racemate composed of equimolar amounts of (R)- and (S)-secbumeton. It is an agrochemical used as a herbicide.


A diamino-1,3,5-triazine that is N,N'-diethyl-1,3,5-triazine-2,4-diamine substituted by a hydroxy group at position 2. It is a metabolite of the herbicide simazine.


METAMITRON

A member of the class of 1,2,4-triazines that is 1,2,4-triazin-5(4H)-one substituted by an amino group at position 4, a methyl group at position 3 and a phenyl group at position 6.


A N-glycosyl-1,2,4-triazine that is the 6-aza analogue of thymidine.


A diamino-1,3,5-triazine that is 1,3,5-triazin-2-ol substituted by an amino group at position 4 and a tert-butylamino group at position 6. It is metabolite of the herbicide terbutylazine.


tritosulfuron

A sulfonamide  that is benzenesulfonamide substituted by a trifluoromethyl group at position 2 and a [4-methoxy-6-(trifluoromethyl)-1,3,5-triazin-2-yl]carbamoyl group at the nitrogen atom.


(S)-sebuthylazine

The (S)-enantiomer of N-(butan-2-yl)-6-chloro-N'-ethyl-1,3,5-triazine-2,4-diamine.


name: 4-morpholinecarbodithioic acid [4-amino-6-(4-methylanilino)-1,3,5-triazin-2-yl]methyl ester


A member of the class of 1,2,4-triazines in which the triazine ring is substituted at positions 3, 5, and 6 by pyridin-2-yl, ([biphenyl]-4-ylmethyl)amin, and methyl groups, respectively. It is an activator of the hypoxia inducible factor (HIF) pathway.


thifensulfuron

An N-sulfonylurea in which the sulfur atom is attached to a 2-carboxythiophen-3-yl group and in which the non-sulfonated nitrogen is substituted by a 4-methoxy-6-methyl-1,3,5-triazin-2-yl group. The corresponding methyl ester, known as thifensulfuron-methyl, is used as a post-emergence herbicide for the control of grass and broad-leaved weeds.


N-isopropylammelide

A dihydroxy-1,3,5-triazine consisting of ammelide bearing an N-isopropyl substituent.


A member of the class of diamino-1,3,5-triazines that is 1,3,5-triazine-2,4-diamine in which the amino groups at positions 2 and 4 are respectively carrying 2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl and 2-(propan-2-ylsulfonyl)phenyl substituents. It is a potent inhibitor of anaplastic lymphoma kinase (ALK), Ack and ROS1 activity (IC50 values are 3.5, 5.8 and 8.9 nM respectively) and exhibits anti-cancer properties.


A member of the class of 1,3,5-triazines that is 1,3,5-triazine substituted by at least one chloro group at unspecified position.


triafamone

A methoxy-1,3,5-triazine that is 1,3,5-triazine substituted by 2-{[(difluoromethyl)sulfonyl](methyl)amino}-3-fluorobenzoyl, methoxy and methoxy groups at positions 2, 4, and 6, respectively. It is a herbicide developed by Bayer CropScience AG for weed control in rice and its mode of action is inhibition of the enzyme acetolactate synthase.


atraton

A diamino-1,3,5-triazine that is N-ethyl-N'-(propan-2-yl)-1,3,5-triazine-2,4-diamine substituted by a methoxy group at position 6. It is an agrochemical used as a herbicide.


A tetrazole tautomer where the proton is located on the 1st position.


name: N,N-dimethylcarbamothioic acid O-[4-[2-[(4-chlorophenyl)thio]-1-oxoethyl]-2,6-dimethylphenyl] ester


name: Grade 4 Urinary Tract Obstruction, CTCAE

description: Life-threatening consequences; urgent intervention indicated


Anaplastic Hemispheric Astrocytoma

description: An anaplastic astrocytoma that arises from the cerebral hemispheres.


name: Recurrent Diffuse Hemispheric Glioma, H3 G34-Mutant

description: The reemergence of diffuse hemispheric glioma, H3 G34-mutant after a period of remission.


Frontal Lobe Anaplastic Astrocytoma

description: An anaplastic astrocytoma occurring in the frontal lobe.


Cerebral Hodgkin Lymphoma

description: A Hodgkin lymphoma that arises from the cerebral hemispheres as a primary lesion.


name: Infant-Type Hemispheric Glioma, MET-Altered

description: A high-grade cellular astrocytoma that arises in the cerebral hemisphere and occurs in early childhood. It is characterized by receptor tyrosine kinase fusions in the MET gene.


Parietal Lobe Anaplastic Astrocytoma

description: An anaplastic astrocytoma occurring in the parietal lobe.


name: Infant-Type Hemispheric Glioma, ALK-Altered

description: A high-grade cellular astrocytoma that arises in the cerebral hemisphere and occurs in early childhood. It is characterized by receptor tyrosine kinase fusions in the ALK gene.


Temporal Lobe Anaplastic Astrocytoma

description: An anaplastic astrocytoma occurring in the temporal lobe.


name: Unresectable Diffuse Hemispheric Glioma, H3 G34-Mutant

description: Diffuse hemispheric glioma, H3 G34-mutant that is not amenable to surgical resection.


name: Adult Diffuse Hemispheric Glioma, H3 G34-Mutant

description: A diffuse hemispheric glioma, H3 G34-mutant that occurs in young adults.


name: Childhood Cerebral Anaplastic Astrocytoma

description: A cerebral anaplastic astrocytoma that occurs during childhood.


name: Childhood Diffuse Hemispheric Glioma, H3 G34-Mutant

description: A diffuse hemispheric glioma, H3 G34-mutant that occurs during childhood.


name: Infant-Type Hemispheric Glioma, NTRK-Altered

description: A high-grade cellular astrocytoma that arises in the cerebral hemisphere and occurs in early childhood. It is characterized by receptor tyrosine kinase fusions in the NTRK family.


Grade 4 Eye Infection, CTCAE

description: Life-threatening consequences; urgent intervention indicated; enucleation


A hydroxypyridine that is pyridine substituted by hydroxy groups at positions 2,3 and 5 and a chloro group at position 6. It is a metabolite of the agrochemical chlorpyrifos.


name: Grade 3 Salivary Gland or Saliva Changes, CTCAE


A terminal acetylenic compound that is butane carrying a triple bond at position 1.


Vessel Biventricular Override

description: Biventricular origin of a cardiovascular vessel.


name: Oropharyngeal Cancer Pathologic TNM Finding v6

description: A pathologic finding about one or more characteristics of oropharyngeal cancer, following the rules of the TNM AJCC v6 classification system.


name: Oropharyngeal Cancer pTX TNM Finding v6 and v7

description: Oropharyngeal cancer in which the primary tumor cannot be assessed. (from AJCC 6th and 7th Eds.)


name: Oropharyngeal Cancer pM1 TNM Finding v6 and v7

description: Oropharyngeal cancer with distant metastasis. (from AJCC 6th and 7th Eds.)


name: Oropharyngeal Cancer pT4a TNM Finding v6

description: Oropharyngeal cancer with tumor invading the larynx, deep/extrinsic muscle of tongue, medial pterygoid muscles, hard palate, or mandible. (from AJCC 6th Ed.)


Oropharyngeal Cancer pN3 TNM Finding v6

description: Oropharyngeal cancer with metastasis to one or more lymph nodes, more than 6 cm in greatest dimension. (from AJCC 6th Ed.)


Oropharyngeal Cancer pT3 TNM Finding v6

description: Oropharyngeal cancer with tumor size more than 4 centimeters in greatest dimension. (from AJCC 6th Ed.)


name: Oropharyngeal Cancer Pathologic Primary Tumor TNM Finding v6

description: A pathologic finding about one or more characteristics of oropharyngeal cancer, following the rules of the TNM AJCC v6 classification system as they pertain to staging of the primary tumor.


name: Oropharyngeal Cancer pN2b TNM Finding v6 and v7

description: Oropharyngeal cancer with metastasis in two or more ipsilateral nodes, none more than 6 cm in greatest dimension. (from AJCC 6th and 7th Eds.)


name: Oropharyngeal Cancer pT0 TNM Finding v6 and v7

description: Oropharyngeal cancer with no evidence of a primary tumor. (from AJCC 6th and 7th Eds.)


name: Oropharyngeal Cancer pN1 TNM Finding v6 and v7

description: Oropharyngeal cancer with metastasis to a single ipsilateral lymph node, 3 cm or less in greatest dimension. (from AJCC 6th and 7th Eds.)


name: Oropharyngeal Cancer pT2 TNM Finding v6 and v7

description: Oropharyngeal cancer with tumor size more than 2 centimeters, but not more than 4 centimeters in greatest dimension. (from AJCC 6th and 7th Eds.)


name: Oropharyngeal Cancer Pathologic Distant Metastasis TNM Finding v6

description: A pathologic finding about one or more characteristics of oropharyngeal cancer, following the rules of the TNM AJCC v6 classification system as they pertain to distant metastases.


name: Oropharyngeal Cancer pN0 TNM Finding v6 and v7

description: Oropharyngeal cancer with no metastasis to regional lymph nodes. (from AJCC 6th and 7th Eds.)


Oropharyngeal Cancer pMX TNM Finding v6

description: Oropharyngeal cancer in which distant metastasis cannot be assessed. (from AJCC 6th Ed.)


name: Oropharyngeal Cancer Pathologic Regional Lymph Nodes TNM Finding v6

description: A pathologic finding about one or more characteristics of oropharyngeal cancer, following the rules of the TNM AJCC v6 classification system as they pertain to staging of regional lymph nodes.


name: Oropharyngeal Cancer pN2c TNM Finding v6 and v7

description: Oropharyngeal cancer with metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension. (from AJCC 6th and 7th Eds.)


name: Oropharyngeal Cancer pN2a TNM Finding v6 and v7

description: Oropharyngeal cancer with metastasis to a single ipsilateral lymph node, more than 3 cm, but not more than 6 cm in greatest dimension. (from AJCC 6th and 7th Eds.)


name: Oropharyngeal Cancer pTis TNM Finding v6 and v7

description: Oropharyngeal cancer with a finding of carcinoma in situ. (from AJCC 6th and 7th Eds.)


name: Oropharyngeal Cancer pT1 TNM Finding v6 and v7

description: Oropharyngeal cancer with tumor size 2 centimeters or less in greatest dimension. (from AJCC 6th and 7th Eds.)


name: Oropharyngeal Cancer pNX TNM Finding v6 and v7

description: Oropharyngeal cancer in which the regional lymph nodes cannot be assessed. (from AJCC 6th and 7th Eds.)


name: Epithelioid Hemangioendothelioma with WWTR1-CAMTA1 Gene Fusion

description: Epithelioid hemangioendothelioma characterized by a t(1;3)(p36;q23-q25) translocation, resulting in a WWTR1-CAMTA1 gene fusion. This translocation and associated gene fusion occur in more than 90% of epithelioid hemangioendotheliomas.


An organic heterooctacyclic compound that is 1H,1'H-2,2'-biindole in which the nitrogens have undergone formal oxidative coupling to positions 2 and 5 of 3-amino-N,2-dimethyloxolane-3-carboxamide (the 2R,3R,5S product), and in which the 3 and 3' positions of the biindole moiety have also undergone formal oxidative coupling to positions 3 and 4 of 1,5-dihydro-2H-pyrrol-2-one.


Grade 3 Hyperglycemia, CTCAE

description: Insulin therapy initiated; hospitalization indicated


Liver Pain, CTCAE

description: An adverse event characterized by pain originating in the liver.


A para-terphenyl that is the 6'-O-desmethyl deriavtive of  terphenyllin. Isolated from Penicillium chermesinum, it exhibits inhibitory activity against alpha-glucosidase.


name: Laryngeal Inflammatory Myofibroblastic Tumor

description: An inflammatory myofibroblastic tumor that arises from the larynx.


KADSURENIN L

A neolignan with formula C23H28O6, originally isolated from Piper kadsura.


Grade 2 Cushingoid, CTCAE

description: Moderate symptoms; medical intervention indicated


Grade 2 Tendon Reflex Decreased, CTCAE

description: Ankle reflex absent; other reflexes reduced


name: Atherosclerosis of Unspecified Type of Bypass Graft(s) of the Left Leg with Ulceration of Other Part of Foot

description: Evidence of atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of other part of foot.


name: Grade 4 Lower Extremity Vein Intra-Operative Injury, CTCAE


A trisaccharide that is beta-D-galactopyranose in which the hydroxy groups at positions 2 and 3 have each been converted into the corresponding beta-D-glucopyranoside.


description: Evidence of inhalant abuse with inhalant-induced psychotic disorder.


CYCLOMORUSIN

An extended flavonoid that is cyclomulberrin in which the hydroxy group at position 10 has undergone oxidative cyclisation to position 3 of the 3-methylbut-2-en-1-yl substituent, with migration of the double bond into conjugation with the aromatic ring. It is a moderate inhibitor of acetylcholinesterase (IC50 = 16.2 - 36.6 muM), and a  strong inhibitor of platelet-activating factor (PAF; 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) induced platelet aggregation.


A beta-D-galactoside that is the 4-methoxyphenyl glycoside of a disaccharide consisting of a 3-O-sulfo-beta-D-glucuronic acid residue linked (1->3) to beta-D-galactose.


Orbital emphysema

description: The presence of air or gas in the subcutaneous tissue of the orbit of the eye.


Any anthocyanidin glucoside in which a 6-O-(4-hydroxycinnamoyl)-beta-D-glucosyl residue is attached at position 3 (R groups may be H).


name: Pheochromocytoma and Paraganglioma pM1a TNM Finding v8

description: Distant metastasis to only bone. (from AJCC 8th Ed.)


Grade 4 Urostomy Stenosis, CTCAE

description: Life-threatening consequences; urgent operative intervention indicated


name: Grade 1 Pancreas or Pancreatic Duct Stricture or Stenosis, CTCAE


A dihydroxyflavanone having the two hydroxy groups located at the C-4' and -7 positions and two additional methoxy substituent at the C-3' and 8-positions.


dimethoxyflavanone

A methoxyflavanone that is flavanone with two methoxy substituents.


A dimethoxyflavanone that is naringenin in which the hydroxy groups at positions 4' and 7 are replaced by methoxy groups.


pisonivanol

A dihydroxyflavanone that is (2S)-flavanone substituted by hydroxy groups at positions 3 and 7 and methoxy groups at positions 5 and 6. It has been isolated from Pisonia aculeata.


A dimethoxyflavanone that is (2S)-(-)-kurarinone in which the hydroxy group at position 2' is replaced by a methoxy group. Isolated from the roots of Sophora flavescens, it exhibits cytotoxicity against human myeloid leukemia HL-60 cells.


methyl hesperidin

A flavanone glycoside that is hesperidin in which the hydroxy group at position 3' has been replaced by a methoxy group.


A dimethoxyflavanone that is flavanone substituted by methoxy groups at positions 5 and 7 and hydroxy groups at positions 6 and 4'.


An extended flavonoid that is 3',4'-methylenedioxyflavanone substituted by methoxy groups at positions 5 and 7 and a 2-hydroxy-3-methyl-3-butenyl moiety at position 8 (the 2S stereoisomer). Isolated from the stem barks of Pongamia pinnata, it acts as a an inducer of quinone reductase, a phase II enzyme that protects cells against reactive, toxic and potentially carcinogenic species.


homoferreirin

A dihydroxyflavanone that is flavanone substituted by hydroxy groups at positions 5 and 7 and methoxy groups at positions 2' and 4' respectively.


A dimethoxyflavanone that is 5,7-dimethoxyflavanone substituted by a formyl group at position 8. Isolated from the stem bark of Pongamia pinnata, it acts as a an inducer of quinone reductase, a phase II enzyme that protects cells against reactive, toxic and potentially carcinogenic species.


name: Corrected Prolonged QT Interval by ECG Finding

description: An electrocardiographic finding in which the QTc interval corrected for heart rate is prolonged. Thresholds for different age, gender, and patient populations exist. (CDISC)


name: Hydroxychloroquine-triggered QTc Interval Prolongation

description: QTc interval prolongation that is seen as an adverse event in some patients with co-morbid cardiovascular disease who are treated with hydroxychloroquine.


9-ribosyl-trans-zeatin 5'-diphosphate

A purine ribonucleoside 5'-diphosphate that is ADP substituted at position N-6 by a (2E)-4-hydroxy-3-methylbut-2-en-1-yl group.


cytidine 5'-monophosphate

A pyrimidine ribonucleoside 5'-monophosphate having cytosine as the nucleobase.


Major species at pH 7.3.


TuMP

A ribonucleoside monophosphate that is tubercidin with a phosphate group replacing the hydrogen on the 5'-hydroxy group.


A (2'->5')-dinucleotide made up from guanosine-5'-triphosphate and adenosine-5'-monophosphate residues


An L-lysyl ester obtained by formal condensation of the carboxy group of L-lysine with the 3'-hydroxy group of AMP.


A ribonucleoside 5'-monophosphate having (2S)-2-amino-4-(6-methyl-9-oxo-4,9-dihydro-3H-imidazo[1,2-a]purin-7-yl)butanoic acid as the nucleobase.


A nucleoside 3',5'-cyclic phosphate that is cAMP in which the nitrogen atom at position 7 on the purine fragment is replaced by a methine (C-H) group.


A purine ribonucleoside 5'-tetraphosphate compound having 5'-xanthosyl residues at the P(1)- and P(4)-positions.


A 2',3'-cyclic purine nucleotide that is GMP in which the hydroxy groups at the 2' and 3' positions have been converted into the corresponding cyclic phosphate.


guanyl ribonucleotide

A purine ribonucleotide where the purine is guanine.


lipoyl-AMP

A purine ribonucleoside 5'-monophosphate having adenine as the nucleobase and a lipoyl group attached to one of the phosphate OH groups.


A pyrimidine ribonucleoside 5'-monophosphate having 5-aminomethyl-2-thiouracil as the nucleobase.


6-deoxyinosine 5'-phosphate

The 5'-monophosphate of 6-deoxyinosine.


A 2',3'-cyclic purine nucleotide that is AMP in which the hydroxy groups at the 2' and 3' positions have been converted into the corresponding cyclic phosphate.


A 3',5'-cyclic purine nucleotide that is 3',5'-cyclic AMP in which the hydrogen at position 2 on the purine fragment is replaced by a 6-aminohexylthio group.


N(4)-acetylcytidine 5'-monophosphate

A pyrimidine ribonucleoside 5'-monophosphate having N(4)-acetylcytosine as the nucleobase.


purine ribonucleotide

Any ribonucleotide that has a purine nucleobase.


A 3',5'-cyclic purine nucleotide that is 3',5'-cyclic GMP in which the hydrogen at position 2 on the purine fragment is replaced by a 4-chlorophenylthio group.


adenosine 5'-hexadecylphosphate

An adenosine 5'-phosphate that is the monohexadecyl ester of AMP.


A cyclic purine dinucleotide that consists of AMP and GMP units cyclised via 2',5'-linkages.


A cyclic purine dinucleotide that consists of AMP and GMP units cyclised via 3',5'- and 2',5'-linkages respectively.


A purine ribonucleoside 5'-diphosphate that is ADP substituted at position 3' by an N-methylanthraniloyl group.


An L-cysteinyl ester obtained by formal condensation of the carboxy group of L-cysteine with the 3'-hydroxy group of AMP.


A purine ribonucleoside 5'-monophosphate that is AMP substituted at C-2 by a methylthio group and at N-6 by a dimethylallyl group.


A ribonucleotide that is the 3'-dehydro derivative of adenosine 5'-triphosphate.


dodecanoyl-AMP

A fatty acyl-AMP that results from the formal condensation of the phosphoryl group of AMP with the carboxyl group of dodecanoic (lauric) acid.


A purine ribonucleoside 5'-monophosphate compound having 6-aminopurine as the nucleobase.


A (3'->5')-dinucleotide composed from guanosine and cytidine units.


A purine ribonucleoside 5'-monophosphate that is AMP substituted at C-2 by a thio group and at N-6 by a dimethylallyl group.


An L-tryptophan derivative that is the ester obtained by formal condensation of the carboxy group of L-tryptophan with the 3'-hydroxy group of AMP.


NMNH

A nicotinamide mononucleotide that is obtained by addition of hydride to position 4 on the pyridine ring of NMN(+).


adenylyl selenate

The 5'-selenonooxyphosphate ester of adenosine.


cyclic di-GMP

A cyclic purine dinucleotide that is the 3',5'-cyclic dimer of MP.


benzoyl-AMP

A purine ribonucleoside 5'-monophosphate that is adenosine 5'-monophosphate in which one of the hydroxy groups of the phosphate has been condensed with the carboxylic acid group of benzoic acid.


N(4)-methylcytidine 5'-monophosphate

A pyrimidine ribonucleoside 5'-monophosphate having N(4)-methylcytosine as the nucleobase.


A uridine 5'-phosphate that is UMP in which the hydroxy hydrogen at position 3 has been replaced by an enolpyruvyl group.


The N(6)-dimethylallyl derivative of adenosine 5'-monophosphate.


A purine ribonucleoside 5'-diphosphate that is GDP substituted at position 2' by an N-methylanthraniloyl group.


guanosine 3'-monophosphate

A guanosine 3'-phosphate compound with a monophosphate group at the 3'-position.


An L-glutamyl ester obtained by formal condensation of the alpha-carboxy group of L-glutamic acid with the 3'-hydroxy group of AMP.


A purine ribonucleoside 5'-monophosphate that is the 8-oxo form of GMP.


A pyrimidine ribonucleoside 5'-monophosphate having 5-methylaminomethyl-2-thiouracil as the nucleobase.


A nucleoside 3',5'-cyclic phosphate that is 7-deaza-cAMP substituted at position 8 by a chloro group.


A 3',5'-cyclic purine nucleotide that is 3',5'-cyclic GMP in which the hydrogen at position 2 on the purine fragment is replaced by a 6-aminohexylthio group.


A pyrimidine ribonucleoside 3'-monophosphate having uracil as the nucleobase.


carbamoyl adenylate

A purine ribonucleoside 5'-monophosphate that is AMP in which one of the phosphate OH groups substituted by a carbamoyl group


(R)-lipoyl-GMP

An acyclic mixed acid anhydride that results from the formal condensation of the phosphoryl group of GMP with the carboxyl group of lipoic acid.


The N(6)-(1,2-dicarboxyethyl) derivative of adenosine 5'-monophosphate.


adenyl ribonucleotide

A purine riboncleotide where adenine is the purine.


A pyrimidine ribonucleoside 5'-monophosphate having 5-carboxymethylaminouracil as the nucleobase.


An L-isoleucine derivative that is the ester obtained by formal condensation of the carboxy group of L-isoleucine with the 3'-hydroxy group of AMP.


The purine ribonucleoside 5'-monophosphate that is AMP monomethylated on N(6).


A cyclic adenyl ribonucleotide that is cAMP (cyclic adenosine 3',5'-phosphate) in which the hydrogen at position 8 has been replaced by a piperidin-1-yl group. A selective cAMP-dependent protein kinase A (PKA) activator and cAMP analogue with high selectivity for site A of PKA type I and for site B of PKA type II.


An L-leucine derivative that is the ester obtained by formal condensation of the carboxy group of L-leucine with the 3'-hydroxy group of AMP.


A purine ribonucleoside 5'-diphosphate that is the 8-oxo derivative of GDP.


An L-proline derivative that is the ester obtained by formal condensation of the carboxy group of L-proline with the 3'-hydroxy group of AMP.


A 3',5'-cyclic purine nucleotide that is 3',5'-cyclic AMP in which the hydrogen at position 2 on the purine fragment is replaced by a 6-aminohexylamino group


An adenosine 5'-phosphate derivative that has the structure of acetyl-coenzyme A dephosphorylated at C-3' and with a 5''-phospho-D-ribosyl substituent at C-2'.


A purine ribonucleoside 5'-tetraphosphate compound having a 5'-adenosyl residue at the P(1)-position and a 5'-guanosyl residue at the P(4)-position.


formycin 3',5'-cyclic phosphate

A nucleoside 3',5'-cyclic phosphate derived from formycin A.


An acyclic mixed acid anhydride that results from the formal condensation of the phosphoryl group of AMP with the carboxyl group of 4-hydroxybenzoic acid.


5'-adenylyl sulfate

An adenosine 5'-phosphate having a sulfo group attached to one the phosphate OH groups.


2-methyladenosine 5'-monophosphate

A purine ribonucleoside 5'-monophosphate having 2-methyladenine as the nucleobase.


A purine ribonucleoside 5'-monophosphate having N,N-dimethylguanine as the nucleobase.


Major species at pH 7.3.


N(2)-methylguanosine 5'-monophosphate

A purine ribonucleoside 5'-monophosphate that is GMP bearing an N(2)-methyl substituent.


An L-asparaginyl derivative that is the ester obtained by formal condensation of the carboxy group of L-asparagine with the 3'-hydroxy group of AMP.


ribonucleoside 3'-monophosphate

A ribonucleoside monophosphate in which the phosphate group is at the ribosyl 3-position.


6-oxouridine 5'-phosphate

A pyrimidine ribonucleoside 5'-monophosphate that is the 6-oxo derivative of UMP.


A secondary alpha-hydroxy ketone that is adenosine 5'-monophosphate in which the hydroxy group at position 3' is replaced by an oxo group.


long-chain fatty acyl-AMP

A fatty acyl-AMP that results from the formal condensation of the phosphoryl group of AMP with the carboxyl group of any long-chain fatty acid.


A ribonucleoside 5'-monophosphate that is wyosine 5'-monophosphate substituted at position 7 by a 3-amino-3-carboxypropyl group.


An L-serine derivative that is the ester obtained by formal condensation of the carboxy group of L-serine with the 3'-hydroxy group of AMP.


(R)-lipoyl-AMP

A lipoyl-AMP in which the lipoyl moiety has (R)-configuration.


A nucleoside pentaphosphate that is adenosine in which a hexahydrogen pentaphosphate is attached at the 5' position.


A purine ribonucleoside 5'-diphosphate having 7-methyl-7,8-dihydroguanine as the nucleobase.


A  (2'->5')-dinucleotide comprising guanosine and adenosine connected by a 2'->5' linkage and with a phosphate group at the 3'-terminus.


A purine ribonucleoside 5'-diphosphate that is GDP substituted at the 3' position by an N-methylanthraniloyl group.


An L-methionine derivative that is the ester obtained by formal condensation of the carboxy group of L-methionine with the 3'-hydroxy group of AMP.


L-threonylcarbamoyladenylate

A threonine derivative that is L-threonine in which one of the amino hydrogens is substituted by and adenyloxycarbonyl group


An adenosine and a guanosine connected by a 3'->5 phosphate linkage; major species at pH 7.3.; major species at pH 7.3.


A 3',5'-cyclic purine nucleotide that is 3',5'-cyclic AMP in which the exocyclic amino group on the purine fragment is carrying a 6-aminohexyl substituent.


beta-hydroxywybutosine 5'-monophosphate

A ribonucleotide that is the 5'-monophosphate derivative of  beta-hydroxywybutosine.


An acyclic mixed acid anhydride that results from the formal condensation of the phosphoryl group of AMP with the carboxy group of 19-(4-hydroxyphenyl)nonadecanoic acid.


An adenosine bisphosphate having two monophosphate groups at the 3'- and 5'-positions.


7-methylguanosine 5'-diphosphate(1+)

A guanosine 5'-phosphate that consists of guanosine 5'-diphosphate bearing a 7-methyl substituent.


An acyclic mixed acid anhydride that results from the formal condensation of the phosphoryl group of AMP with the carboxyl group of 2-hydroxybenzoic acid.


5-bromouridine 5'-monophosphate

A pyrimidine ribonucleoside 5'-monophosphate having 5-bromouracil as the pyrimidine component.


XDP

A purine ribonucleoside 5'-diphosphate having xanthosine as the nucleobase.


7-methylguanosine 5'-diphosphate

A guanosine 5'-phosphate that consists of guanosine 5'-diphosphate bearing a 7-methyl substituent and having a negatively charged diphosphate group.


2'-O-methylguanosine 5'-monophosphate

A guanosine 5'-phosphate that is the 2'-O-methyl derivative of guanosine 5'-monophosphate.


L-seryl-AMP

A purine ribonucleoside 5'-monophosphate that is adenosine 5'-monophosphate in which one of the hydroxy groups of the phosphate has been condensed with the carboxylic acid group of L-serine.


A  purine ribonucleoside 5'-monophosphate that is adenosine 5'-monophosphate substituted on N-6 by geminal methyl groups.


2'-O-methylcytidine 5'-monophosphate

A pyrimidine ribonucleoside 5'-monophosphate that is CMP monomethylated at position O-2'


A guanosine 5'-phosphate that is the N(2),N(2),N(7)-trimethyl derivative of guanosine 5'-monophosphate.


A glycinyl ester obtained by formal condensation of the carboxy group of glycinne with the 3'-hydroxy group of AMP.


3'-phosphoadenylyl selenate

An organoselenium compound that is adenylyl selenate with the hydroxy at position 3' replaced by a phosphate group.


L-threonyl-AMP

A purine ribonucleoside 5'-monophosphate that is adenosine 5'-monophosphate in which one of the hydroxy groups of the phosphate has been condensed with the carboxylic acid group of L-threonine.


A 3',5'-cyclic purine nucleotide obtained by oxygenation of the nitrogen at position 1 on the purine fragment of 3',5'-cyclic AMP.


A pyrimidine ribonucleoside 5'-monophosphate having uracil as the nucleobase.


propanoyl-AMP

A purine ribonucleoside 5'-monophosphate consisting of adenosine 5'-monophosphate where one of the hydroxy groups of the phosphate has been condensed with propionic acid.


A pyrimidine ribonucleoside 5'-monophosphate having 5-carboxymethylamino-2-thiouracil as the nucleobase.


2'-O-methyladenosine 5'-monophosphate

A adenosine 5'-phosphate that is the 2'-O-methyl derivative of adenosine 5'-monophosphate.


5'-xanthylic acid

A purine ribonucleoside 5'-monophosphate having xanthine as the nucleobase.


9-ribosyl-trans-zeatin 5'-monophosphate

A purine ribonucleoside 5'-monophosphate that is AMP substituted at position N-6 by a (2E)-4-hydroxy-3-methylbut-2-en-1-yl group.


A purine ribonucleoside 5'-tetraphosphate having adenine as the nucleobase.


D-alanyl-AMP

A purine ribonucleoside 5'-monophosphate that is adenosine 5'-monophosphate in which one of the hydroxy groups of the phosphate has been condensed with the carboxylic acid group of D-alanine.


A nucleoside 3',5'-cyclic phosphate that is cGMP in which the nitrogen atom at position 7 on the purine fragment is replaced by a methine (C-H) group


Major species at pH 7.3.


glycyl-AMP

A purine ribonucleoside 5'-monophosphate that is adenosine 5'-monophosphate in which one of the hydroxy groups of the phosphate has been condensed with the carboxylic acid group of glycine.


adenosine 5'-monophosphate

A purine ribonucleoside 5'-monophosphate having adenine as the nucleobase.


N(3)-methyluridine 5'-monophosphate

A pyrimidine ribonucleoside 5'-monophosphate having 3-methyluracil as the nucleobase.


An L-glutaminyl derivative that is the ester obtained by formal condensation of the carboxy group of L-glutamine with the 3'-hydroxy group of AMP.


A guanosine bisphosphate having a diphosphate at the 3'-position and a triphosphate at the 5'-position.


adenosylcobinamide guanosyl diphosphate

A cobalt corrinoid consisting of cobinamide guanosyl diphosphate having a 5'-adenosyl group attached to the central cobalt atom.


A purine ribonucleoside 5'-diphosphate that is ADP substituted at position N-6 by a dimethylallyl (isopentenyl) group.


An L-phenylalanine derivative that is the ester obtained by formal condensation of the carboxy group of L-phenylalanine with the 3'-hydroxy group of AMP.


A pyrimidine ribonucleoside 5'-monophosphate that is the  5-carboxymethylaminomethyl-2'-O-methyl derivative of uridine 5'-monophosphate.


4-demethylwyosine 5'-monophosphate

A ribonucleotide that is the 5'-monophosphate derivative of 4-demethylwyosine.


An adenosine 5'-monophosphate having a salicyl group at the 3'-position; intermediate in mycobactin biosynthesis.


A 3',5'-cyclic purine nucleotide that is 3',5'-cyclic AMP in which the hydrogen at position 2 on the purine fragment is replaced by a dimethylamino group.


An acyclic mixed acid anhydride obtained by condensation of one of the carboxy group of pyridinium-3,5-biscarboxylic acid mononucleotide with the phosphste group of AMP.


An L-alanyl ester obtained by formal condensation of the carboxy group of L-alanine with the 3'-hydroxy group of AMP.


An acyclic mixed acid anhydride obtained by condensation of one of the carboxy group of pyridinium-3-sulfanylcarbonyl-5-carboxylic acid mononucleotide with the phosphste group of AMP.


An adenosine 5'-phosphate derivative that has the structure of coenzyme A dephosphorylated at C-3' and with a 5''-phospho-D-ribosyl substituent at C-2'.


An acyclic mixed acid anhydride that results from the formal condensation of the phosphoryl group of AMP with the carboxyl group of 2-amino-3-hydroxy-4-methylbenzoic acid.


N(3)-methylcytidine 5'-monophosphate

A pyrimidine ribonucleoside 5'-monophosphate having N(3)-methylcytosine as the nucleobase.


An L-valyl ester obtained by formal condensation of the carboxy group of L-valine with the 3'-hydroxy group of AMP.


adenosine thiamine triphosphate

An adenosine 5'-phosphate obtained by formal condensation of the hydroxy group of thiamine with the triphosphate group of ATP.


An adenosine 5'-phosphate derivative that has the structure of coenzyme A dephosphorylated at C-3' and with a 5-triphospho-alpha-D-ribosyl substituent at C-2'.


TDP

A pyrimidine ribonucleoside 5'-diphosphate in which the pyrimidine element is 5-methyluracil.


OROTIDINE MONOPHOSPHATE

A pyrimidine ribonucleoside 5'-monophosphate having 6-carboxyuracil as the nucleobase.


N(7)-methylguanosine 5'-phosphate

A guanosine 5'-phosphate that is the N(7)-methyl derivative of guanosine 5'-monophosphate.


c-GMP-AMP

A cyclic purine dinucleotide that consists of AMP and GMP units cyclised via 3',5'-linkages.


cyclic di-AMP

A cyclic purine dinucleotide that is the 3',5'-cyclic dimer of AMP.


hexadecanoyl-AMP

A fatty acyl-AMP that results from the formal condensation of the phosphoryl group of AMP with the carboxyl group of hexadecanoic (palmitic) acid.


CDP

A pyrimidine ribonucleoside 5'-diphosphate having cytosine as the nucleobase.


A purine ribonucleoside 5'-monophosphate that is the 2-oxo derivative of AMP.


A ribonucleoside 5'-monophosphate that is wyosine 5'-monophosphate substituted at position 7 by a 2-hydroxy-3-amino-3-carboxypropyl group.


name: Phosphoric acid mono-[(2R,3S,4R,5R)-5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl] ester


An L-tyrosyl ester obtained by formal condensation of the carboxy group of L-tyrosine with the 3'-hydroxy group of AMP.


A 3',5'-cyclic purine nucleotide that is 3',5'-cyclic AMP in which the hydrogen at position 2 on the purine fragment is replaced by a 6-aminohexylamino group.


N(1)-methylguanosine 5'-monophosphate

A purine ribonucleoside 5'-monophosphate that is GMP bearing a methyl substituent at position 1.


A cytidine 3'-phosphate compound with a monophosphate group at the 3'-position.


fatty acyl-AMP

An acyl-AMP that results from the formal condensation of the phosphoryl group of AMP with the carboxyl group of any fatty acid.


urate D-ribonucleotide

A purine ribonucleoside 5'-monophosphate consisting of 5'-xanthylic acid having an oxo group at the 8-position.


inosine 3'-monophosphate

An inosine phosphate having a monophosphate group located at the 3'-position.


A guanosine 5'-phosphate that is the N(2),N(2),N(7)-trimethyl derivative of guanosine 5'-triphosphate.


A purine ribonucleoside 5'-monophosphate that is the 2-hydroxylated form of AMP.


An adenosine 5'-phosphate that is coenzyme A in which the phosphate group at position 3' has been replaced by a hydrogen atom. It is an intermediate metabolite in pantothenate and CoA biosynthesis.


An L-aspartic acid derivative that is the ester obtained by formal condensation of the alpha-carboxy group of L-aspartic acid with the 3'-hydroxy group of AMP.


An L-threonine derivative that is the ester obtained by formal condensation of the carboxy group of L-threonine with the 3'-hydroxy group of AMP.


Grade 3 Vagus Nerve Disorder, CTCAE

description: Severe symptoms; limiting self care ADL


A pyranone that is 4-hydroxy-3-methyl-2H-pyran-2-one in which two of the hydrogens of the methyl group are replaced by a cycloprop-2-en-1-yl group and a 3-{[N-(tert-butoxycarbonyl)-beta-alanyl]amino}phenyl group (S-configuration) and in which the hydrogen at position 6 is replaced by a 1-phenylbutan-2-yl group (R-configuration).


Recurrent Sarcoma of the Extremity

description: A sarcoma of the soft tissues or bones of the upper or lower extremity that has recurred after a period of remission.


name: Stage II Small Intestinal Gastrointestinal Stromal Tumor

description: Stage II includes: T3, N0, M0, Mitotic rate: Low.  T3: Tumor more than 5 cm, but not more than 10 cm, in greatest dimension. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Stage III Rectal Cancer AJCC v7

description: Stage III includes: IIIA (T1-T2, N1/N1c, M0); (T1, N2a, M0); IIIB (T3-T4a, N1/N1c, M0); (T2-T3, N2a, M0); (T1-T2, N2b, M0); IIIC (T4a, N2a, M0); (T3-T4a, N2b, M0); (T4b, N1-N2, M0).  T1: Tumor invades submucosa.  T2: Tumor invades muscularis propria.  T3: Tumor invades through the muscularis propria into pericolorectal tissues.  T4a: Tumor penetrates to the surface of the visceral peritoneum.  T4b: Tumor directly invades or is adherent to other organs or structures. N0: No regional lymph node metastasis.  N1: Metastasis in 1-3 regional lymph nodes.  N1c: Tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional lymph node metastasis. N2: Metastasis in four or more regional lymph nodes.  N2a: Metastasis in 4-6 regional lymph nodes.  N2b: Metastasis in seven or more regional lymph nodes.  M0: No distant metastasis.  (AJCC 7th ed.)


Cecum Neuroendocrine Tumor

description: A well differentiated, low, intermediate, or high grade neoplasm with neuroendocrine differentiation that arises from the cecum.


Advanced Colorectal Carcinoma

description: Colorectal carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Hereditary Colon Carcinoma

description: Colon carcinoma that has developed in relatives of patients with a history of colon carcinoma.


Colorectal Neuroendocrine Tumor

description: A well differentiated, low, intermediate, or high grade neoplasm with neuroendocrine differentiation that arises from the colon or rectum.


name: Stage IIB Small Intestinal Cancer AJCC v7

description: Stage IIB includes: T4, N0, M0. T4: Tumor perforates the visceral peritoneum or directly invades other organs or structures (including other loops of small intestine, mesentery, or retroperitoneum more than 2 cm, and abdominal wall by way of serosa; for duodenum only, invasion of pancreas or bile duct). N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Intestinal Neuroendocrine Tumor G2

description: A well differentiated, intermediate grade neoplasm with neuroendocrine differentiation that arises from the small or large intestine. The mitotic count is 2-20 per 10 HPF and/or the Ki67 index is 3 to 20 percent.


Intestinal Neuroendocrine Carcinoma

description: An aggressive, high-grade, and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the small or large intestine. The mitotic count is more than 20 per 10 HPF. It is classified as either small or large cell neuroendocrine carcinoma based on the size of the malignant cells, the prominence of the nucleoli, and the amount of cytoplasm.


Non-Neoplastic Intestinal Disorder

description: A disorder that affects the small or large intestine and is non-neoplastic in nature. Representative examples include acute appendicitis, colitis, and inflammatory bowel disease.


Colorectal Conventional Adenoma

description: A benign, premalignant colorectal neoplasm composed of dysplastic epithelium. The descriptor "conventional" distinguishes this from lesions in the serrated pathway. (WHO 2019)


Stage II Colorectal Cancer AJCC v8

description: Stage II includes: IIA: T3, N0, M0; IIB: T4a, N0, M0; IIC: T4b, N0, M0. T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). T4b: Tumor directly invades or adheres to adjacent organs or structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Colon Serrated Adenocarcinoma

description: A rare, invasive colon adenocarcinoma characterized by the presence of a malignant infiltrate with serrated glandular architecture.


Jejunal web

description: The formation of tissue in the lumen of the jejunum that results in partial obstruction.


name: Adenoma of the Colon with Intramucosal Adenocarcinoma

description: An intramucosal malignant glandular epithelial infiltrate in a colonic adenoma.  There is no evidence of submucosal invasion.


Rectal Conventional Adenoma

description: A benign, premalignant rectal neoplasm composed of dysplastic epithelium. The descriptor "conventional" distinguishes this from lesions in the serrated pathway. (WHO 2019)


name: Small Intestinal Undifferentiated Carcinoma

description: A carcinoma that arises from the small intestine.  It is composed of malignant epithelial cells which do not display evidence of glandular, squamous, or transitional cell differentiation.


Colon Conventional Adenoma

description: A benign, premalignant colon neoplasm composed of dysplastic epithelium. The descriptor "conventional" distinguishes this from lesions in the serrated pathway. (WHO 2019)


Unresectable Colon Adenocarcinoma

description: A colon adenocarcinoma that is not amenable to surgical resection.


Stage IIC Colon Cancer AJCC v7

description: Stage IIC includes: T4b, N0, M0. T4b: Tumor directly invades or is adherent to other organs or structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 7th ed.)


Colon Cancer by AJCC v8 Stage

description: A term that refers to the staging of colon cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to adenocarcinomas, high-grade neuroendocrine carcinomas, and squamous cell carcinomas of the colon. (from AJCC 8th Ed.)


Colorectal Perineurioma

description: A perineurioma that arises from the colon or rectum.  It usually presents as a small sessile polyp.


Colitis aggravated

description: Exacerbation of an underlying colitis.


name: Small Intestinal Enterochromaffin Cell Serotonin-Producing Neuroendocrine Tumor

description: A well differentiated neuroendocrine tumor that arises from the small intestine and produces serotonin.


Stage IVB Colon Cancer AJCC v8

description: Stage IVB includes: Any T, Any N, M1b. M1b: Metastasis to two or more sites or organs without peritoneal metastasis.  (AJCC 8th ed.)


name: Stage I Colorectal Cancer AJCC v6 and v7

description: Stage I includes: (T1, N0, M0); (T2, N0, M0).  T1: Tumor invades submucosa.  T2: Tumor invades muscularis propria.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Metastatic Colon Carcinoma

description: A carcinoma that arises from the colon and has metastasized to another anatomic site.


Childhood Rectal Carcinoma

description: A rare carcinoma of the rectum that occurs during childhood.


Ulcer of rectum

description: A circumscribed inflammatory and necrotic erosive lesion in the mucosa surface of the rectum.


Stage IIIA Colorectal Cancer AJCC v7

description: Stage IIIA includes: (T1-T2, N1/N1c, M0); (T1, N2a, M0). T1: Tumor invades submucosa.  T2: Tumor invades muscularis propria.  N1: Metastasis in 1-3 regional lymph nodes.  N1c: Tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional lymph node metastasis. N2a: Metastasis in 4-6 regional lymph nodes.  M0: No distant metastasis.  (AJCC 7th ed.)


Clostridium colitis

description: An acute inflammatory disorder of the colon secondary to infection with any species of the bacterial genus Clostridium. Symptoms include acute diarrhea, abdominal pain, and myalgia.


Stage IIB Colorectal Cancer AJCC v8

description: Stage IIB includes: T4a, N0, M0. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage II Colon Cancer AJCC v8

description: Stage II includes: IIA: T3, N0, M0; IIB: T4a, N0, M0; IIC: T4b, N0, M0. T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). T4b: Tumor directly invades or adheres to adjacent organs or structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


name: Stage II Duodenal Neuroendocrine Tumor AJCC v8

description: Stage II includes: (T2, N0, M0); (T3, N0, M0). T2: Tumor invading the muscularis propria or measuring more than 1 cm. T3: Tumor invading the pancreas or peripancreatic adipose tissue. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Duodenal web

description: Partial or complete obstruction of the duodenal lumen due to the presence of a membranous web.


Clostridium sordellii colitis

description: Inflammation of the colon resulting from Clostridium Sordelli.


name: Stage 0 Small Intestinal Adenocarcinoma AJCC v8

description: Stage 0 includes: Tis, N0, M0. Tis: High grade dysplasia/carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Grade 2 Colorectal Adenocarcinoma

description: A colorectal adenocarcinoma characterized by the presence of a malignant cellular infiltrate with 50-95% glandular formation.


name: Small Intestinal Neuroendocrine Tumor G2

description: A well differentiated, intermediate grade neoplasm with neuroendocrine differentiation that arises from the small intestine. The mitotic count is 2-20 per 10 HPF and/or the Ki67 index is 3 to 20 percent.


Colorectal Neuroendocrine Tumor G3

description: A well differentiated, high grade neoplasm with neuroendocrine differentiation that arises from the colon and rectum. The Ki-67 index is higher than 20%.


Stage IVB Colorectal Cancer AJCC v7

description: Stage IVB includes: Any T, Any N, M1b.  M1b: Metastases in more than one organ/site or the peritoneum. (AJCC 7th ed.)


Rectosigmoid cancer recurrent

description: The reemergence of rectosigmoid carcinoma after a period of remission.


Ileal Neuroendocrine Tumor G3

description: A neuroendocrine tumor grade 3 that arises from the ileum.


Stage IIIC Rectal Cancer AJCC v7

description: Stage IIIC includes: (T4a, N2a, M0); (T3-T4a, N2b, M0); (T4b, N1-N2, M0). T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor penetrates to the surface of the visceral peritoneum. T4b: Tumor directly invades or is adherent to other organs or structures. N1: Metastasis in 1-3 regional lymph nodes. N2: Metastasis in four or more regional lymph nodes. N2a: Metastasis in 4-6 regional lymph nodes. N2b: Metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 7th ed.)


Stage III Rectosigmoid Cancer AJCC v6

description: Stage III includes: IIIA (T1-T2, N1, M0); IIIB (T3-T4, N1, M0); IIIC (Any T, N2, M0). N1: Metastasis in 1 to 3 regional lymph nodes.  N2: Metastasis in 4 or more regional lymph nodes. M0: No distant metastasis. (AJCC 6th ed.)


Rectosigmoid Cancer by AJCC v7 Stage

description: A term that refers to the staging of rectosigmoid carcinoma according to the American Joint Committee on Cancer, 7th edition.


name: Metastatic Malignant Colorectal Neoplasm

description: A malignant neoplasm that arises in the colon or rectum that has spread from its original site of growth to other anatomic sites.


Colorectal Cowden-Associated Polyp

description: A hamartomatous polyp that arises from the colon and rectum and it is associated with the presence of Cowden syndrome.


name: Colorectal Adenoma with Moderate Dysplasia

description: An adenoma that arises from the colon or rectum.  It is characterized by the presence of moderate epithelial dysplasia.


Metastatic Rectal Carcinoma

description: A carcinoma that arises from the rectum and has metastasized to another anatomic site.


name: Stage IV Ileal Neuroendocrine Tumor AJCC v8

description: Stage IV includes: (T1, N0, N1, N2, M1); (T2, N0, N1, N2, M1); (T3, N0, N1, N2, M1); (T4, N0, N1, N2, M1). T1: Tumor invading lamina propria or submucosa and measuring 1 cm or less in size. T2: Tumor invading muscularis propria or measuring more than 1 cm in size. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. T4: Tumor invading visceral peritoneum (serosa) or other organs or adjacent structures. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis in less than 12 nodes. N2: Large mesenteric masses (larger than 2 cm) and/or extensive nodal deposits (12 or greater), especially those that encase the superior mesenteric vessels. M1: Distant metastasis. (AJCC 8th ed.)


Jejunal Neuroendocrine Tumor G3

description: A neuroendocrine tumor grade 3 that arises from the jejunum.


Stage IVC Colon Cancer AJCC v8

description: Stage IVC includes: Any T, Any N, M1c. M1c: Metastasis to the peritoneal surface alone or with other site or organ metastases. (AJCC 8th ed.)


Rectal Cancer by AJCC v6 Stage

description: A term that refers to the staging of rectal carcinoma according to the American Joint Committee on Cancer, 6th edition.


Chronic Active Colitis

description: Chronic colitis with superimposed neutrophilic mucosal infiltrates. It is usually seen during exacerbations of inflammatory bowel disease.


name: Chronic Non-Specific Multiple Ulcers of the Small Intestine

description: A clinical condition characterized by persistent and occult gastrointestinal bleeding, multiple sharply demarcated lesions surrounded by normal mucosa in the small intestine, which do not affect the muscular layer. It shares many features with NSAID-induced enteropathy. The etiology is not fully elucidated but may include a genetic component.


name: Small Intestinal Cancer by AJCC v7 Stage

description: A term that refers to the staging of small intestinal cancer according to the American Joint Committee on Cancer, 7th edition.


Stage IIIA Rectal Cancer AJCC v8

description: Stage IIIA includes: (T1-T2, N1/N1c, M0); (T1, N2a, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N1c: No regional lymph nodes are positive, but there are tumor deposits in the subserosa, mesentery, or nonperitonealized pericolic, or perirectal/mesorectal tissues. N2a: Four to six regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)


name: Stage I Ileal Neuroendocrine Tumor AJCC v8

description: Stage I includes: T1, N0, M0. T1: Tumor invading lamina propria or submucosa and measuring 1 cm or less in size. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Sigmoid Colon Neuroendocrine Tumor G1

description: A well differentiated, low grade neuroendocrine neoplasm that arises from the sigmoid colon. The mitotic count is less than 2 per 10 HPF and/or the Ki67 index is equal to or less than 2 percent.


name: Non-infective Inflammatory Bowel Disease

description: A disease of the intestines that is inflammatory but not infectious.


Colorectal Inflammatory Polyp

description: A non-neoplastic polypoid lesion in the colon and rectum.  It may arise in a background of inflammatory bowel disease or colitis.  It is characterized by the presence of a distorted epithelium, inflammation, and fibrosis.


Colorectal Benign Granular Cell Tumor

description: A granular cell tumor that arises from the colon or rectum and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.


Refractory Colon Carcinoma

description: Colon carcinoma that is resistant to treatment.


Stage IVB Colorectal Cancer AJCC v8

description: Stage IVB includes: Any T, Any N, M1b. M1b: Metastasis to two or more sites or organs without peritoneal metastasis.  (AJCC 8th ed.)


Rectal Mucositis

description: An inflammatory process affecting the mucous membrane of the rectum.


Small Intestinal Myeloid Sarcoma

description: An extramedullary myeloid tumor that arises from the small intestine. It often presents with abdominal pain and obstruction.


Early Stage Colorectal Carcinoma

description: A stage term referring to colorectal carcinoma that is limited to the colon/rectum or local lymph nodes, without metastasis to distant anatomic sites.


Colorectal Cancer by AJCC v6 Stage

description: A term that refers to the staging of colorectal carcinoma according to the American Joint Committee on Cancer, 6th edition.


Colorectal Neuroendocrine Neoplasm

description: A neoplasm with neuroendocrine differentiation that arises from the colon or rectum. It includes neuroendocrine tumors (well-differentiated neuroendocrine neoplasms) and neuroendocrine carcinomas (poorly differentiated neuroendocrine neoplasms).


Unresectable Colon Carcinoma

description: Colon carcinoma that is not amenable to surgical resection.


Childhood Colorectal Carcinoma

description: A rare colorectal carcinoma that occurs during childhood.


Grade 1 Colorectal Adenocarcinoma

description: A colorectal adenocarcinoma characterized by the presence of a malignant cellular infiltrate with more than 95% glandular formation.


Duodenal Neuroendocrine Tumor G2

description: A well differentiated, intermediate grade neoplasm with neuroendocrine differentiation that arises from the duodenum. The mitotic count is 2-20 per 10 HPF and/or the Ki67 index is 3 to 20 percent.


Stage II Colon Cancer AJCC v7

description: Stage II includes: IIA (T3, N0, M0); IIB (T4a, N0, M0); IIC (T4b, N0, M0). T3: Tumor invades through the muscularis propria into pericolorectal tissues.  T4a: Tumor penetrates to the surface of the visceral peritoneum.  T4b: Tumor directly invades or is adherent to other organs or structures. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Stage IVA Rectal Cancer AJCC v8

description: Stage IVA includes: Any T, Any N, M1a. M1a: Metastasis to one site or organ without peritoneal metastasis. (AJCC 8th ed.)


Colorectal Neuroendocrine Tumor G2

description: A well differentiated, intermediate grade neoplasm with neuroendocrine differentiation that arises from the colon or rectum. The mitotic count is 2-20 per 10 HPF and/or the Ki67 index is 3 to 20 percent.


Locally Recurrent Colorectal Carcinoma

description: The reemergence of colorectal carcinoma after a period of remission, at or adjacent to the site of the original tumor.


Refractory Colorectal Carcinoma

description: Colorectal carcinoma that does not respond to treatment.


Colon Intramucosal Adenocarcinoma

description: An adenocarcinoma that arises from the colonic glandular epithelium and invades the lamina propria or muscularis mucosa but not the submucosa.


Colonic tubulovillous adenoma

description: A neoplasm that arises from the glandular epithelium of the colonic mucosa. It is characterized by tubular and villous architectural patterns. The neoplastic glandular cells have dysplastic features.


name: Microsatellite Stable Colorectal Carcinoma

description: Colorectal carcinoma characterized by the absence of microsatellite instability.


Visceral Myopathy 1

description: An autosomal dominant type of functional intestinal obstruction caused by mutation(s) in the ACTG2 gene, encoding actin, gamma-enteric smooth muscle.


Small intestine carcinoma stage III

description: Stage III includes: IIIA (Any T, N1, M0); IIIB (Any T, N2, M0); N1: Metastasis in 1-3 regional lymph nodes.  N2: Metastasis in four or more regional lymph nodes.  M0: No distant metastasis.  (AJCC 7th ed.)


Intestinal Neuroendocrine Tumor G3

description: A well differentiated, high grade neoplasm with neuroendocrine differentiation that arises from the small or large intestine. The Ki-67 index is higher than 20%.


name: Colorectal Cribriform Comedo-Type Adenocarcinoma

description: A rare, invasive colorectal adenocarcinoma characterized by the presence of malignant cribriform glands with central necrotic changes.


Refractory Colon Adenocarcinoma

description: Colon adenocarcinoma that is resistant to treatment.


Stage IIC Colon Cancer AJCC v8

description: Stage IIC includes: T4b, N0, M0. T4b: Tumor directly invades or adheres to adjacent organs or structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IV Colorectal Cancer AJCC v7

description: Stage IV includes: IVA: (Any T, Any N, M1a); IVB: (Any T, Any N, M1b).  M1a: Metastasis confined to one organ or site (e.g., liver, lung, ovary, nonregional node).  M1b: Metastases in more than one organ/site or the peritoneum. (AJCC 7th ed.)


name: Stage II Jejunal Neuroendocrine Tumor AJCC v8

description: Stage II includes: (T2, N0, M0); (T3, N0, M0). T2: Tumor invading muscularis propria or measuring more than 1 cm in size. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage II Rectal Cancer AJCC v8

description: Stage II includes: IIA: T3, N0, M0; IIB: T4a, N0, M0; IIC: T4b, N0, M0. T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). T4b: Tumor directly invades or adheres to adjacent organs or structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Unresectable Rectal Adenocarcinoma

description: A rectal adenocarcinoma that is not amenable to surgical resection.


Small Intestinal Ulcer

description: A circumscribed inflammatory and necrotic erosive lesion in the mucosa surface of the small intestine.


name: Stage III Small Intestinal Adenocarcinoma AJCC v8

description: Stage III includes: IIIA: Any T, N1, M0; IIIB: Any T, N2, M0. N1: Metastasis in one or two regional lymph nodes. N2: Metastasis in three or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Colorectal Neuroendocrine Carcinoma

description: An aggressive, high-grade, and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the colon or rectum. The mitotic count is more than 20 per 10 HPF. It is classified as either small or large cell neuroendocrine carcinoma based on the size of the malignant cells, the prominence of the nucleoli, and the amount of cytoplasm.


name: Stage IIIA Small Intestinal Cancer AJCC v7

description: Stage IIIA includes: Any T, N1, M0. N1: Metastasis in 1-3 regional lymph nodes.  M0: No distant metastasis.  (AJCC 7th ed.)


name: Intestinal Composite Gangliocytoma/Neuroma and Neuroendocrine Tumor

description: A usually indolent neuroendocrine neoplasm that arises in the intestine. Patients may present with gastrointestinal hemorrhage. It is a triphasic tumor consisting of a mixture of epithelioid neuroendocrine cells, Schwann-like cells, and ganglion cell-like elements.


Rectosigmoid Mucinous Adenocarcinoma

description: An invasive adenocarcinoma of the rectosigmoid area characterized by the presence of pools of extracellular mucin.  Malignant glandular epithelial cells are present in the mucin collections.  Mucin constitutes more than 50% of the lesion.


name: Stage 0 Rectosigmoid Cancer AJCC v6 and v7

description: Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ: intraepithelial or invasion of the lamina propria.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th eds.)


Stage IVC Rectal Cancer AJCC v8

description: Stage IVC includes: Any T, Any N, M1c. M1c: Metastasis to the peritoneal surface alone or with other site or organ metastases. (AJCC 8th ed.)


Colon Neuroendocrine Tumor G3

description: A well differentiated, high grade neoplasm with neuroendocrine differentiation that arises from the colon. The Ki-67 index is higher than 20%.


Rectal Cancer by AJCC v7 Stage

description: A term that refers to the staging of rectal carcinoma according to the American Joint Committee on Cancer, 7th edition.


Rectal Neuroendocrine Carcinoma

description: An aggressive, high-grade, and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the rectum. The mitotic count is more than 20 per 10 HPF. It is classified as either small or large cell neuroendocrine carcinoma based on the size of the malignant cells, the prominence of the nucleoli, and the amount of cytoplasm.


Stage IVA Colorectal Cancer AJCC v7

description: Stage IVA includes: Any T, Any N, M1a.  M1a: Metastasis confined to one organ or site (e.g., liver, lung, ovary, nonregional node).  (AJCC 7th ed.)


Stage IVB Colon Cancer AJCC v7

description: Stage IVB includes: Any T, Any N, M1b. M1b: Metastases in more than one organ/site or the peritoneum. (AJCC 7th ed.)


Cecum Neuroendocrine Tumor G2

description: A well differentiated, intermediate grade neoplasm with neuroendocrine differentiation that arises from the cecum. The mitotic count is 2-20 per 10 HPF and/or the Ki67 index is 3 to 20 percent.


Grade 2 Colon Adenocarcinoma

description: A colon adenocarcinoma characterized by the presence of a malignant cellular infiltrate with 50-95% glandular formation.


Stage III Colorectal Cancer AJCC v6

description: Stage Group III is subdivided into IIIA (T1-2, N1, M0), IIIB (T3-4, N1, M0) or IIIC (any T, N2 M0).  T1: Tumor invades the submucosa.  T2: Tumor invades muscularis propria.  T3: Tumor invades through the muscularis propria into the subserosa or into non-peritonealized pericolic or perirectal tissues.  T4: Tumor directly invades other organs or structures, and/or perforates visceral peritoneum.  N1: Metastasis in 1 to 3 regional lymph nodes N2: Metastasis in 4 or more regional lymph nodes.  M0: No distant metastasis.  (AJCC 6th ed.)


name: Stage IV Small Intestinal Adenocarcinoma AJCC v8

description: Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)


Grade 1 Colon Adenocarcinoma

description: A colon adenocarcinoma characterized by the presence of a malignant cellular infiltrate with more than 95% glandular formation.


name: Small Intestinal Neuroendocrine Tumor G3

description: A well differentiated, high grade neoplasm with neuroendocrine differentiation that arises from the small intestine. The Ki-67 index is higher than 20%.


Carcinoma of sigmoid colon

description: A carcinoma that arises from the sigmoid colon.


Stage II Colorectal Cancer AJCC v6

description: Stage Group II is subdivided into IIA and IIB on the basis of whether the primary tumor is T3 or T4, respectively.  T3: Tumor invades through the muscularis propria into the subserosa, or into non-peritonealized pericolic or perirectal tissues.  T4: Tumor directly invades other organs or structures, and/or perforates visceral peritoneum. (AJCC 6th ed.)


Suspected Necrotizing Enterocolitis

description: The diagnosis assigned when a health care practitioner feels strongly the patient has necrotizing enterocolitis, but lacks definitive proof.


Colorectal Angiosarcoma

description: An angiosarcoma that arises from the colon or rectum.


Locally Advanced Colon Adenocarcinoma

description: Colon adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


name: Colorectal Mixed Adenoneuroendocrine Carcinoma

description: A carcinoma that arises from the colon or rectum and is characterized by the presence of a malignant glandular epithelial component and a malignant neuroendocrine component.  At least 30 percent of either component should be present for the diagnosis to be made.


name: Colorectal Small Cell Neuroendocrine Carcinoma

description: An aggressive, high-grade, and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the colon or rectum.  It is characterized by the presence of malignant small cells.


name: Metastatic Microsatellite Stable Colon Carcinoma

description: Microsatellite stable colon carcinoma that has spread from its original site of growth to another anatomic site.


Stage IIIA Colon Cancer AJCC v7

description: Stage IIIA includes: (T1-T2, N1/N1c, M0); (T1, N2a, M0). T1: Tumor invades submucosa. T2: Tumor invades muscularis propria. N1: Metastasis in 1-3 regional lymph nodes. N1c: Tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional lymph node metastasis. N2a: Metastasis in 4-6 regional lymph nodes. M0: No distant metastasis. (AJCC 7th ed.)


name: Small Intestinal Mixed Adenoneuroendocrine Carcinoma

description: A carcinoma that arises from the small intestine and is characterized by the presence of a malignant glandular epithelial component and a malignant neuroendocrine component.  At least 30 percent of either component should be present for the diagnosis to be made.


name: Small Intestinal High Grade Intraepithelial Neoplasia

description: A precancerous neoplastic process that affects the small intestine.  It is characterized by moderate or severe epithelial dysplasia and complex architectural alterations of the mucosal epithelium.  There is no evidence of invasion.


Rectal Neuroendocrine Tumor G2

description: A well differentiated, intermediate grade neoplasm with neuroendocrine differentiation that arises from the rectum. The mitotic count is 2-20 per 10 HPF and/or the Ki67 index is 3 to 20 percent.


Congenital atresia of large intestine

description: A malformation characterized by the absence of a normal opening in a part of the large intestine.


name: Small Intestinal Low Grade Intraepithelial Neoplasia

description: A precancerous neoplastic process that affects the small intestine.  It is characterized by mild epithelial dysplasia and mild architectural alterations of the mucosal epithelium.  There is no evidence of invasion.


Locally Advanced Colorectal Carcinoma

description: A colorectal carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Stage 0 Rectal Cancer AJCC v8

description: Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ, intramucosal carcinoma (involvement of lamina propria with no extension through muscularis mucosae). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IV Colon Cancer AJCC v6

description: Stage IV includes: (Any T, Any N, M1).  M1: Distant metastasis. (AJCC 6th ed.)


Colorectal Sarcoma

description: A malignant soft tissue neoplasm that arises from the colon or rectum.  Representative examples include angiosarcoma, Kaposi sarcoma, and leiomyosarcoma.


Microsatellite Stable Colon Carcinoma

description: Colon carcinoma characterized by the absence of microsatellite instability.


Typhlitis

description: Inflammation of the cecum, usually accompanied by neutropenia.


Stage II Colon Cancer

description: Stage II includes: IIA (T3, N0, M0); IIB (T4, N0, M0).  T3: Tumor invades through the muscularis propria or into non-peritonealized pericolic or perirectal tissues.  T4: Tumor directly invades other organs or structures, and/or perforates visceral peritoneum.  N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th ed.)


name: Stage II Small Intestinal Adenocarcinoma AJCC v8

description: Stage II includes: IIA: T3, N0, M0; IIB: T4, N0, M0. T3: Tumor invading through the muscularis propria into the subserosa, or extending into nonperitonealized perimuscular tissue (mesentery or retroperitoneum) without serosal penetration. For T3 tumors, the nonperitonealized perimuscular tissue is, for the jejunum and ileum, part of the mesentery and, for the duodenum in areas where serosa is lacking, part of the interface with the pancreas. T4: Tumor perforating the visceral peritoneum or directly invading other organs or structures (e.g., other loops of small intestine, mesentery of adjacent loops of bowel, and abdominal wall by way of serosa; for duodenum only, invasion of pancreas or bile duct). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


name: Small Intestinal Composite Gangliocytoma/Neuroma and Neuroendocrine Tumor

description: A usually indolent neuroendocrine neoplasm that arises in the small intestine. Patients may present with gastrointestinal hemorrhage. It is a triphasic tumor consisting of a mixture of epithelioid neuroendocrine cells, Schwann-like cells, and ganglion cell-like elements.


Cecal Infection

description: An infectious process affecting the cecum.


Stage IIIB Rectal Cancer AJCC v8

description: Stage IIIB includes: (T3-T4a, N1/N1c, M0); (T2-T3, N2a, M0); (T1-T2, N2b, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N1c: No regional lymph nodes are positive, but there are tumor deposits in the subserosa, mesentery, or nonperitonealized pericolic, or perirectal/mesorectal tissues. N2a: Four to six regional lymph nodes are positive. N2b: Seven or more regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)


Metastatic Carcinoma in the Rectum

description: A carcinoma that has spread to the rectum from another anatomic site.


name: Stage III Ileal Neuroendocrine Tumor AJCC v8

description: Stage III includes: (T1, N1, N2, M0); (T2, N1, N2, M0); (T3, N1, N2, M0); (T4, N0, M0); (T4, N1, N2, M0). T1: Tumor invading lamina propria or submucosa and measuring 1 cm or less in size. T2: Tumor invading muscularis propria or measuring more than 1 cm in size. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. T4: Tumor invading visceral peritoneum (serosa) or other organs or adjacent structures. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis in less than 12 nodes. N2: Large mesenteric masses (larger than 2 cm) and/or extensive nodal deposits (12 or greater), especially those that encase the superior mesenteric vessels. M0: No distant metastasis. (AJCC 8th ed.)


Refractory Rectal Adenocarcinoma

description: Rectal adenocarcinoma that is resistant to treatment.


Colon Hodgkin Lymphoma

description: An extranodal Hodgkin lymphoma that arises from the colon.


Tubular adenoma of colon

description: A usually polypoid neoplasm that arises from the glandular epithelium of the colonic mucosa. It is characterized by a tubular architectural pattern. The neoplastic glandular cells have dysplastic features.


Sigmoid Colon Neuroendocrine Tumor

description: A well differentiated, low, intermediate, or high grade neoplasm with neuroendocrine differentiation that arises from the sigmoid colon.


Stage II Colorectal Cancer AJCC v7

description: Stage II includes: IIA (T3, N0, M0); IIB (T4a, N0, M0); IIC (T4b, N0, M0). T3: Tumor invades through the muscularis propria into pericolorectal tissues.  T4a: Tumor penetrates to the surface of the visceral peritoneum.  T4b: Tumor directly invades or is adherent to other organs or structures. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Small intestine carcinoma stage I

description: Stage I includes: (T1, N0, M0); (T2, N0, M0). T1: Tumor invades lamina propria or submucosa.  T2: Tumor invades muscularis propria. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


name: Unresectable Microsatellite Stable Colorectal Carcinoma

description: Microsatellite stable colorectal carcinoma that is not amenable to surgical resection.


Stage IIIC Rectal Cancer AJCC v8

description: Stage IIIC includes: (T4a, N2a, M0); (T3-T4a, N2b, M0); (T4b, N1-N2, M0). T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). T4b: Tumor directly invades or adheres to adjacent organs or structures. N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N2: Four or more regional lymph nodes are positive. N2a: Four to six regional lymph nodes are positive. N2b: Seven or more regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)


description: Adenocarcinoma that arises from the periampullary region and is not amenable to surgical resection.


name: Inflammatory Bowel Disease-Associated Colorectal Adenocarcinoma

description: A colorectal adenocarcinoma that develops in patients with a history of inflammatory bowel disease.


name: Small Intestinal Adenocarcinoma by AJCC v8 Stage

description: A term that refers to the staging of small intestinal adenocarcinoma according to the American Joint Committee on Cancer, 8th edition. Nonadenocarcinomas arising in the small intestine should have a TNM assigned but are not assigned a stage classification. (from AJCC 8th Ed.)


Colon Cancer by AJCC v7 Stage

description: A term that refers to the staging of colon carcinoma according to the American Joint Committee on Cancer, 7th edition.


Stage III Colon Cancer

description: Stage III includes: IIIA (T1-T2, N1, M0); IIIB (T3-T4, N1, M0); IIIC (Any T, N2, M0). N1: Metastasis in 1 to 3 regional lymph nodes.  N2: Metastasis in 4 or more regional lymph nodes. M0: No distant metastasis. (AJCC 6th ed.)


Rectal Cancer by AJCC v8 Stage

description: A term that refers to the staging of rectal cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to adenocarcinomas, high-grade neuroendocrine carcinomas, and squamous cell carcinomas of the rectum. (from AJCC 8th Ed.)


Ascending Colon Neuroendocrine Tumor

description: A well differentiated, low, intermediate, or high grade neoplasm with neuroendocrine differentiation that arises from the ascending colon.


name: Small Intestinal Adenosquamous Carcinoma

description: A carcinoma that arises from the small intestine.  It is composed of malignant glandular cells and malignant squamous cells.


Radiation enteritis of intestine

description: Inflammation of the small intestine caused by radiation exposure.


Colorectal Intraepithelial Neoplasia

description: A precancerous neoplastic process that affects the colon or rectum.  It is characterized by low or high grade dysplasia of the mucosal epithelium.  There is no evidence of invasion.


name: Ulcerative Colitis-Associated Colorectal Adenocarcinoma

description: A colorectal adenocarcinoma that develops in patients with a history of ulcerative colitis.  Such carcinomas are usually multiple and flat.  Histologically, they are usually mucinous or signet-ring cell type.


name: Colorectal Enterochromaffin Cell Serotonin-Producing Neuroendocrine Tumor

description: A well differentiated neuroendocrine tumor that arises from the colon or rectum and produces serotonin.


Small intestine carcinoma stage II

description: Stage II includes: IIA (T3, N0, M0); IIB (T4, N0, M0).  T3: Tumor invades through the muscularis propria into the subserosa or into the nonperitonealized perimuscular tissue (mesentery or retroperitoneum) with extension 2 cm or less.  T4: Tumor perforates the visceral peritoneum or directly invades other organs or structures (including other loops of small intestine, mesentery, or retroperitoneum more than 2 cm, and abdominal wall by way of serosa; for duodenum only, invasion of pancreas or bile duct). N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Small Intestinal Kaposi Sarcoma

description: A Kaposi sarcoma that arises from the small intestine.


Colon Serrated Polyposis

description: The presence of multiple serrated polyps in the colon. The polyps are predominantly sessile serrated adenomas/polyps. A minority of the polyps are microvesicular variants of hyperplastic polyps. According to some authors, the polyps are proximal to the sigmoid colon. According to others, the polyps are distributed throughout the entire colon.


Grade 2 Rectal Adenocarcinoma

description: A rectal adenocarcinoma characterized by the presence of a malignant cellular infiltrate with 50-95% glandular formation.


Stage IV Colon Cancer AJCC v7

description: Stage IV includes: IVA: (Any T, Any N, M1a); IVB: (Any T, Any N, M1b).  M1a: Metastasis confined to one organ or site (e.g., liver, lung, ovary, nonregional node).  M1b: Metastases in more than one organ/site or the peritoneum. (AJCC 7th ed.)


Duodenal Extraskeletal Osteosarcoma

description: An extraskeletal osteosarcoma affecting the duodenum.


name: Stage IV Small Intestinal Gastrointestinal Stromal Tumor

description: Stage IV includes: (Any T, N1, M0, Mitotic rate: Any rate); (Any T, Any N, M1, Mitotic rate: Any rate).  N1: Regional lymph node metastasis.  M1: Distant metastasis. (AJCC 7th ed.)


Small Intestinal Mucositis

description: An inflammatory process affecting the mucous membrane of the small intestine.


Stage IIIB Colorectal Cancer AJCC v8

description: Stage IIIB includes: (T3-T4a, N1/N1c, M0); (T2-T3, N2a, M0); (T1-T2, N2b, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N1c: No regional lymph nodes are positive, but there are tumor deposits in the subserosa, mesentery, or nonperitonealized pericolic, or perirectal/mesorectal tissues. N2a: Four to six regional lymph nodes are positive. N2b: Seven or more regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)


Carcinoma in situ of small intestine

description: Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 7th ed.)


Hypermutated Colorectal Carcinoma

description: A colorectal carcinoma characterized by a high mutational rate caused by DNA mismatch repair deficiency or POLE/POLD1 driver mutations.


name: Stage IIA Small Intestinal Cancer AJCC v7

description: Stage IIA includes: T3, N0, M0. T3: Tumor invades through the muscularis propria into the subserosa or into the nonperitonealized perimuscular tissue (mesentery or retroperitoneum) with extension 2 cm or less.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Colorectal hyperplastic polyp

description: A serrated polypoid lesion that arises in the colon and rectum.  It is usually found in the distant colon and it rarely produces symptoms.  This group includes goblet cell rich, mucin poor, and microvesicular hyperplastic polyps.


Stage IIIA Colorectal Cancer AJCC v8

description: Stage IIIA includes: (T1-T2, N1/N1c, M0); (T1, N2a, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N1c: No regional lymph nodes are positive, but there are tumor deposits in the subserosa, mesentery, or nonperitonealized pericolic, or perirectal/mesorectal tissues. N2a: Four to six regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)


Colon Hyperplastic Polyp

description: A serrated polypoid lesion that arises in the colon.  It is usually found in the distant colon and it rarely produces symptoms.  This group includes goblet cell rich, mucin poor, and microvesicular hyperplastic polyps.


name: Transverse Colon Neuroendocrine Tumor G2

description: A well differentiated, intermediate grade neoplasm with neuroendocrine differentiation that arises from the transverse colon. The mitotic count is 2-20 per 10 HPF and/or the Ki67 index is 3 to 20 percent.


name: Colorectal High Grade Intraepithelial Neoplasia

description: A precancerous neoplastic process that affects the colon or rectum.  It is characterized by moderate or severe epithelial dysplasia and complex architectural alterations of the mucosal epithelium.  There is no evidence of invasion.


Stage IIA Colorectal Cancer AJCC v8

description: Stage IIA includes: T3, N0, M0. T3: Tumor invades through the muscularis propria into pericolorectal tissues. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


name: Metastatic Colorectal Mucinous Adenocarcinoma

description: Colorectal mucinous adenocarcinoma that has spread from the original site of growth to other anatomic sites.


Small Intestinal Medullary Carcinoma

description: A carcinoma that arises from the small intestine.  It is characterized by the presence of malignant epithelial cells with vesicular nucleus, distinct nucleolus, and abundant pink cytoplasm.


Distal Colon Carcinoma

description: A colon carcinoma that arises from the splenic flexure, descending colon, or sigmoid colon.


Stage I Rectal Cancer AJCC v8

description: Stage I includes: (T1, N0, M0); (T2, N0, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IVA Colon Cancer AJCC v7

description: Stage IVA includes: Any T, Any N, M1a. M1a: Metastasis confined to one organ or site (e.g., liver, lung, ovary, nonregional node). (AJCC 7th ed.)


Stage IIC Rectal Cancer AJCC v7

description: Stage IIC includes: T4b, N0, M0. T4b: Tumor directly invades or is adherent to other organs or structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 7th ed.)


name: Colorectal Large Cell Neuroendocrine Carcinoma

description: An aggressive, high-grade, and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the colon or rectum.  It is characterized by the presence of malignant large cells.


name: Colon Large Cell Neuroendocrine Carcinoma

description: An aggressive, high-grade, and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the colon. It is characterized by the presence of malignant large cells.


Stage I Rectal Cancer AJCC v6 and v7

description: Stage I includes: (T1, N0, M0); (T2, N0, M0).  T1: Tumor invades submucosa.  T2: Tumor invades muscularis propria.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Colorectal Hodgkin Lymphoma

description: An extranodal Hodgkin lymphoma that arises from the colon or rectum.


name: Small Intestinal Gastrin-Producing Neuroendocrine Tumor

description: A gastrin-producing neuroendocrine tumor that arises from the small intestine.  It is characterized by the presence of uniform cells that form pseudorosettes.  The neoplastic cells have uniform nuclei and small amount of eosinophilic cytoplasm.


name: Unresectable Small Intestinal Adenocarcinoma

description: Small intestinal adenocarcinoma that is not amenable to surgical resection.


name: Colorectal Adenoma with Severe Dysplasia

description: An adenoma that arises from the colon or rectum.  It is characterized by the presence of severe epithelial dysplasia.


name: Small intestine carcinoma non-resectable

description: Carcinoma of the small intestine not amendable to resection.


Grade 1 Rectal Adenocarcinoma

description: A rectal adenocarcinoma characterized by the presence of a malignant cellular infiltrate with more than 95% glandular formation.


Recurrent Colorectal Adenocarcinoma

description: The reemergence of colorectal adenocarcinoma after a period of remission.